Cabinet Overrides Health Advisers in Controversial Puberty Blocker Ban

The decision by the Cabinet to ban new prescriptions of puberty blockers for treating gender dysphoria has raised significant concerns, particularly regarding the apparent disregard for health officials’ advice. Newly released documents indicate that ministers dismissed the recommendations from the Ministry of Health when implementing this controversial policy.

On March 15, 2024, the High Court issued a temporary order preventing the enforcement of the ban until further legal arguments can be heard next year. The Court highlighted that the Cabinet’s decision seemed politically motivated and diverged from medical advice outlined in the Regulatory Impact Statement (RIS). The health officials had previously indicated that maintaining the status quo was the more prudent option.

The ban, which took effect on March 15, 2024, followed a review published by the Ministry of Health last year. This review assessed the evidence surrounding the benefits and risks associated with puberty blockers. It concluded that there was insufficient robust evidence supporting either the positive impacts of the medications on mental health or the negative effects they might cause. Consequently, the Ministry advised that patients should be informed of this lack of evidence when discussing treatment options.

Despite these findings, the Ministry of Health recommended exploring the need for tighter regulations surrounding new prescriptions. Both Matt Doocey, Minister of Mental Health, and the former health minister Shane Reti expressed their support for regulatory measures to limit new prescriptions. A proposal was consulted early in 2024, but progress on the matter stalled until Simeon Brown, the current Health Minister, announced the ban last month.

Documents released late on March 14, 2024, reveal that officials had developed various options based on the earlier consultation. Brown presented four potential pathways to the Cabinet: maintaining the status quo, enhancing monitoring by the Ministry of Health, regulating new prescriptions while expanding gender care services, or implementing an outright ban. The Cabinet ultimately chose the third option, which Brown stated would be reassessed following a scientific trial on puberty blockers set to begin in the UK.

In the advice that accompanied the Cabinet paper, officials clearly preferred either maintaining the status quo or enhancing monitoring. They noted that no option could definitively advance health objectives, asserting that the status quo provided a framework for clinicians to evaluate the risks and benefits for each patient. The Ministry emphasized that this approach would allow for personalized care in consultation with patients and their families.

The documents further explained that the regulated ban would likely offer less benefit compared to maintaining the current system. Although the ban prioritizes caution due to the lack of evidence regarding safety and efficacy, it may hinder clinicians’ ability to act in the best interests of individual patients. Officials warned that some young people might resort to obtaining puberty blockers online, risking their health with unregulated and potentially harmful medications.

A child impact assessment included with the regulatory advice indicated that restricting access to puberty blockers could negatively affect young individuals with gender-related health needs. The assessment recommended against such policies from a child-centered perspective.

Despite the Ministry’s opposition to other options not being explicitly stated in the paper presented to the Cabinet, the documents indicated that the UK scientific trial on puberty blockers would extend until at least 2031. This timeline suggests that the ban may not be a temporary measure.

Following the Cabinet’s decision, the Ministry of Health, along with Health NZ, began exploring options for expanding gender care services. The proposals included establishing a national center of excellence, creating four regional hubs with specialized expertise, and implementing a locally driven model with district hubs. However, the follow-up paper to the Cabinet included a fourth option—an online resource page that directs individuals to existing services. This option, noted for requiring no additional funding, was ultimately selected by the Cabinet, raising concerns about its effectiveness in addressing current service issues.

When asked why the government chose to override the Ministry of Health’s advice, Brown refrained from directly addressing whether the decision was politically motivated. He affirmed the government’s support for the regulations preventing new prescriptions for puberty blockers and stated that legal advice regarding the next steps is being sought.

As this situation unfolds, the implications of the Cabinet’s decision and its potential effects on young people seeking gender-affirming treatment remain a matter of significant concern for health advocates and stakeholders.